Emedastine-ketoconazole: Pharmacokinetic and pharmacodynamic interactions in healthy volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 39, Issue 3, 2001, Pages 102-109

  Herranz, U ^a   Rusca, A ^a   Assandri, A ^a  

^a Cross Research SA Phase I Unit   (Switzerland)

Author keywords

Antihistaminic; Drug interaction; Emedastine; Ketoconazole; QTc

Indexed keywords

ANTIHISTAMINIC AGENT; CHLORPHENIRAMINE; CYTOCHROME P450; DIPHENHYDRAMINE; EMEDASTINE; ISOPROTEIN; KETOCONAZOLE; KETOTIFEN; PARACETAMOL; PROMETHAZINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG HALF LIFE; DRUG METABOLISM; DRUG SCREENING; ELECTROCARDIOGRAM; FATIGUE; HEADACHE; HUMAN; HUMAN EXPERIMENT; LASSITUDE; MALE; NAUSEA; NORMAL HUMAN; PARAMETER; QT INTERVAL; SOMNOLENCE; STATISTICS; STEADY STATE; VERTIGO; VOLUNTEER; XEROSTOMIA;

EID: 0035105949     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP39102     Document Type: Article

References (18)

1. Single and multiple dose pharmacokinetics in male healthy volunteers administered emedastine orally according to a once daily (4 mg od) or twice daily (2 mg bid) dose regimen. Two-way crossover, randomized study
2. Loratadine administered concomitantly with erythromycin: Pharmacokinetic and electrocardiographic evaluations
3. Clinical significance of interactions with antifungal agents
4. Emedastine tolerability and pharmacokinetics in male healthy volunteers after administration of 4 single ascending doses from 1 to 8 mg by the oral route
5. Radioreceptor assay for a new antiallergic agent, 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl) benzimidazole difumarate (KB-2413) in plasma
6. Selective and sensitive determination of an antiallergic agent, emedastine difumarate (KG-2413), in human plasma by the radioreceptor assay combined with a high-performance liquid chromatography
7. Cross-reactivities of active metabolites in the radioreceptor assay of an antiallergic agent, 1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)- 1H-benzimidazole difumarate (KG-2413)]
8. The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans
9. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences
10. Therapeutic effect of emedastine (KG-2413) on urticaria
11. Clinical evaluation of KG-2413 (emedastine difumarate) on chronic urticaria by multicenter double-blind study - Comparative study between 2 mg/day, 4 mg/day, and ketotifen fumarate
12. Identification of human P450 isoforms involved in the metabolism emedastine difumarate
13. 1-receptor-antagonist emedastine in healthy volunteers
14. Clinical evaluation of emedastine difumarate (KG-2413) for the treatment of all year-round allergic rhinitis
15. Torsades de pointes after terfenadine-itraconazole interaction
16. General pharmacology of 1-(2-ethoxy-ethyl)-2-(4-methyl-1-homopiperazinyl)benzimidazole difumarate. 1st Communication: Effects on the central nervous system
17. 1-blockers on neuropharmacological and behavioural effects including 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)benzimidazole difumarate (KB-2413), a new antiallergic agent